Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
measles vaccine live attenuated
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intramuscular
01
Overview
**Measles vaccine live attenuated** is a preparation of live, weakened (attenuated) measles virus designed to induce active immunity against measles infection. The attenuated virus simulates natural infection, prompting the immune system to mount an effective antibody and cellular immune response, thus conferring protection against future measles virus exposure. This vaccine is primarily administered for the prevention of measles (rubeola) and has markedly reduced the incidence of this potentially serious disease, which can cause pneumonia, encephalitis, and death, especially in infants and adults. The vaccine is no longer available as a monovalent product in many regions; it is most commonly used in combination vaccines such as MMR (measles, mumps, rubella). Its use is recommended for routine immunization in children as well as adults without evidence of measles immunity.
- Brand names
- AttenuvaxMevilin
- Other names
- measles virus vaccine livelive attenuated measles vaccinerubeola vaccinemeasles vaccinemeasles virus vaccine
Beyond the preview
Go deeper on measles vaccine live attenuated.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on measles vaccine live attenuated.